Flagship Harbor Advisors LLC Raises Stock Position in abrdn Life Sciences Investors (NYSE:HQL)

Flagship Harbor Advisors LLC grew its holdings in shares of abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 36.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 340,877 shares of the company's stock after buying an additional 90,436 shares during the quarter. Flagship Harbor Advisors LLC owned 1.18% of abrdn Life Sciences Investors worth $4,326,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. BankPlus Trust Department purchased a new stake in shares of abrdn Life Sciences Investors during the 4th quarter valued at about $28,000. Steward Partners Investment Advisory LLC raised its position in abrdn Life Sciences Investors by 379.8% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,860 shares of the company's stock worth $64,000 after purchasing an additional 3,847 shares during the period. Wealthcare Advisory Partners LLC purchased a new stake in abrdn Life Sciences Investors in the 1st quarter worth about $131,000. Cambridge Investment Research Advisors Inc. purchased a new stake in abrdn Life Sciences Investors in the 1st quarter worth about $134,000. Finally, Landscape Capital Management L.L.C. purchased a new stake in abrdn Life Sciences Investors in the 4th quarter worth about $154,000. 32.21% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, major shareholder Saba Capital Management, L.P. sold 48,623 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $12.58, for a total transaction of $611,677.34. Following the transaction, the insider now directly owns 3,188,405 shares of the company's stock, valued at approximately $40,110,134.90. This trade represents a 1.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold 177,158 shares of company stock valued at $2,136,750 in the last ninety days. 10.06% of the stock is owned by company insiders.

abrdn Life Sciences Investors Stock Performance

abrdn Life Sciences Investors stock traded up $0.01 during midday trading on Thursday, reaching $12.77. The stock had a trading volume of 45,436 shares, compared to its average volume of 106,992. abrdn Life Sciences Investors has a 52-week low of $10.55 and a 52-week high of $15.90. The company has a fifty day moving average of $12.49 and a 200 day moving average of $12.98.

abrdn Life Sciences Investors Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Thursday, May 22nd will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 13.47%. The ex-dividend date is Thursday, May 22nd.

About abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.